192 related articles for article (PubMed ID: 17287403)
21. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis.
Heaney AP; Horwitz GA; Wang Z; Singson R; Melmed S
Nat Med; 1999 Nov; 5(11):1317-21. PubMed ID: 10546001
[TBL] [Abstract][Full Text] [Related]
22. Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours.
Trouillas J; Delgrange E; Wierinckx A; Vasiljevic A; Jouanneau E; Burman P; Raverot G
Neuroendocrinology; 2019; 109(1):70-76. PubMed ID: 30943495
[TBL] [Abstract][Full Text] [Related]
23. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
[TBL] [Abstract][Full Text] [Related]
25. Effects of silencing connexin43 on expression of pituitary tumor-transforming gene in prolactinomas.
Wang H; Zhang Y; Zhou A; Zhang R; Meng Q
Neurol Res; 2015 Feb; 37(2):153-8. PubMed ID: 25023895
[TBL] [Abstract][Full Text] [Related]
26. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Wass JA; Harris AL
Br J Cancer; 2000 Apr; 82(8):1441-5. PubMed ID: 10780524
[TBL] [Abstract][Full Text] [Related]
27. Expression and clinical significance of Wnt players and survivin in pituitary tumours.
Formosa R; Gruppetta M; Falzon S; Santillo G; DeGaetano J; Xuereb-Anastasi A; Vassallo J
Endocr Pathol; 2012 Jun; 23(2):123-31. PubMed ID: 22327960
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses.
Evans CO; Moreno CS; Zhan X; McCabe MT; Vertino PM; Desiderio DM; Oyesiku NM
Pituitary; 2008; 11(3):231-45. PubMed ID: 18183490
[TBL] [Abstract][Full Text] [Related]
29. [Aggressive and resistant-to-treatment pituitary tumors].
Cuny T; Chanson P
Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S3-12. PubMed ID: 24356289
[TBL] [Abstract][Full Text] [Related]
30. Molecular screening of pituitary adenomas for gene mutations and rearrangements.
Herman V; Drazin NZ; Gonsky R; Melmed S
J Clin Endocrinol Metab; 1993 Jul; 77(1):50-5. PubMed ID: 8100831
[TBL] [Abstract][Full Text] [Related]
31. The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas.
Finelli P; Pierantoni GM; Giardino D; Losa M; Rodeschini O; Fedele M; Valtorta E; Mortini P; Croce CM; Larizza L; Fusco A
Cancer Res; 2002 Apr; 62(8):2398-405. PubMed ID: 11956103
[TBL] [Abstract][Full Text] [Related]
32. Sex differences in the development of prolactinoma in mice overexpressing hCGβ: role of TGFβ1.
Faraoni EY; Camilletti MA; Abeledo-Machado A; Ratner LD; De Fino F; Huhtaniemi I; Rulli SB; Díaz-Torga G
J Endocrinol; 2017 Mar; 232(3):535-546. PubMed ID: 28096433
[TBL] [Abstract][Full Text] [Related]
33. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
34. ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation.
Principe M; Chanal M; Karam V; Wierinckx A; Mikaélian I; Gadet R; Auger C; Raverot V; Jouanneau E; Vasiljevic A; Hennino A; Raverot G; Bertolino P
Endocr Relat Cancer; 2018 Sep; 25(9):795-806. PubMed ID: 30012586
[TBL] [Abstract][Full Text] [Related]
35. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern.
Burgess JR; Shepherd JJ; Parameswaran V; Hoffman L; Greenaway TM
J Clin Endocrinol Metab; 1996 May; 81(5):1841-5. PubMed ID: 8626844
[TBL] [Abstract][Full Text] [Related]
36. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas.
Xie W; Liu C; Wu D; Li Z; Li C; Zhang Y
Oncotarget; 2016 Aug; 7(32):50883-50894. PubMed ID: 27438154
[TBL] [Abstract][Full Text] [Related]
38. Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.
Mahboobifard F; Bidari-Zerehpoosh F; Davoudi Z; Panahi M; Dargahi L; Pourgholami MH; Sharifi G; Izadi N; Jorjani M
Pituitary; 2020 Jun; 23(3):232-245. PubMed ID: 32026205
[TBL] [Abstract][Full Text] [Related]
39. [Differential expression analysis of prolactinoma-related microRNAs].
Chen YX; Li Q; Wang CD; Su ZP; Li WQ; Chen XB; Wu ZB
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(5):320-3. PubMed ID: 22490835
[TBL] [Abstract][Full Text] [Related]
40. Pituitary tumors: prognostic indicators.
Saeger W
Endocrine; 2005 Oct; 28(1):57-66. PubMed ID: 16311411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
